10-K: Artiva Biotherapeutics Navigates Autoimmune and Cancer Therapies in 2024

Artiva Biotherapeutics advances AlloNK, an allogeneic NK cell therapy, targeting autoimmune diseases and cancers, with initial data expected in the first half of 2025.

Summary

• Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing allogeneic NK cell therapies for autoimmune diseases and cancers.
• Their lead product candidate, AlloNK, is being evaluated in a Phase 1/1b trial for SLE and a basket IIT in multiple autoimmune indications.
• The company expects to report initial data on autoimmune indications from at least one of their trials in the first half of 2025.
• AlloNK was the first allogeneic, off-the-shelf NK cell therapy candidate to receive IND clearance for administration to a patient with an autoimmune disease in a U.S. clinical trial, and to receive FDA Fast Track designation in an autoimmune disease.
• The company believes AlloNK in combination with B-cell targeted mAbs represents the next-generation of B-cell depleting therapies because it aims to address important limitations of auto-CAR-T, including scalability, safety and cost.
• Global sales for autoimmune disease treatments reached approximately $160 billion in 2023.
• The company has a manufacturing-first approach, with a 9,000 square foot cGMP-compliant cell production center capable of producing enough vials to treat over 250 to 1,000 autoimmunity patients annually.
• The company was founded in 2019 as a spin out of GC Cell, granting them exclusive, worldwide, ex-APAC, rights to GC Cells NK cell manufacturing technology and programs.
• As of March 19, 2025, the number of shares of Registrants Common Stock outstanding was 24,363,119.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as clinical trial progress and strategic collaborations, the company is still in the early stages of development and faces significant financial and regulatory challenges.

Positives

• AlloNK has shown complete responses in B-NHL patients in an ongoing Phase 1/2 clinical trial.
• The company's versatile mAb combination approach allows flexibility to tailor targeting approach to specific B-cell subpopulations.
• The proprietary manufacturing process allows for scalable and potentially cost effective AlloNK production.
• AlloNK is a non-genetically modified cell therapy, which has not shown integrating vector-induced secondary malignancies.
• The AlloNK cell approach aims to broaden community access, drive improved patient experience, improve clinical recruitment timelines and expand commercial opportunity.
• Strategic execution led to first-mover advantage in autoimmune disease.
• The company has leading scientific advisors who guide their development strategy in autoimmune disease.

Negatives

• The company has incurred significant losses since inception and may never achieve or maintain profitability.
• The company will need to obtain substantial additional funding to complete the development and any commercialization of their current and any future product candidates, which may cause dilution to stockholders.
• The company's approach to the development of NK cell-based product candidates is unproven.
• The company's product candidates are based on novel technologies, which makes it difficult to predict the time and cost of developing product candidates and obtaining regulatory approval.
• The company is substantially dependent on the success of their lead product candidate, AlloNK, which is in early clinical development.
• Current clinical data regarding the efficacy of NK cell therapies against autoimmune diseases are limited.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome.
• The company's product candidates may cause serious adverse events or undesirable side effects.
• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process subject to various external factors beyond the company's control that may cause delays or complications.
• The affected populations for the company's product candidates may be smaller than the company or third parties currently project, which may affect the addressable markets for the company's product candidates.
• The manufacture of cell therapy products is novel, complex and subject to multiple risks.
• The company currently relies on GC Cell for the manufacturing of certain of their product candidates.
• The company is dependent on third parties to acquire, ship and store their cord blood units, NK cell master cell banks and drug product lots, viral vectors, and master and working feeder cell banks.
• The company's cell therapy products depend on the availability of reagents and specialized materials and equipment, including cord blood and viral vectors.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company depends substantially on intellectual property rights granted under their agreements with GC Cell.
• The company will need to expand their organization, and they may experience significant challenges in managing this growth as they build their capabilities, which could disrupt their operations.
• The company's future success depends on their ability to retain their key personnel and to attract, retain and motivate qualified personnel.

Risks

• The company has a limited operating history and has not completed any clinical trials.
• The company will need to obtain substantial additional funding to complete the development and any commercialization of their current and any future product candidates.
• The company's approach to the development of NK cell-based product candidates is unproven.
• The company's product candidates are based on novel technologies, which makes it difficult to predict the time and cost of developing product candidates and obtaining regulatory approval.
• The company is substantially dependent on the success of their lead product candidate, AlloNK, which is in early clinical development.
• Current clinical data regarding the efficacy of NK cell therapies against autoimmune diseases are limited.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome.
• The company's product candidates may cause serious adverse events or undesirable side effects.
• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process subject to various external factors beyond the company's control that may cause delays or complications.
• The affected populations for the company's product candidates may be smaller than the company or third parties currently project, which may affect the addressable markets for the company's product candidates.
• The company's collaboration agreements with Affimed, GC Cell and any future collaborations with third parties to develop or commercialize their product candidates mean that their prospects with respect to the product candidates involved will depend in significant part on the success of those collaborations.
• The manufacture of cell therapy products is novel, complex and subject to multiple risks.
• The company currently relies on GC Cell for the manufacturing of certain of their product candidates.
• The company is dependent on third parties to acquire, ship and store their cord blood units, NK cell master cell banks and drug product lots, viral vectors, and master and working feeder cell banks.
• The company's cell therapy products depend on the availability of reagents and specialized materials and equipment, including cord blood and viral vectors.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company depends substantially on intellectual property rights granted under their agreements with GC Cell.
• The company will need to expand their organization, and they may experience significant challenges in managing this growth as they build their capabilities, which could disrupt their operations.
• The company's future success depends on their ability to retain their key personnel and to attract, retain and motivate qualified personnel.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as they advance their current and future product candidates through preclinical and clinical development, continue to build their operations and transition to operating as a public company.

Management Comments

• Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.

Industry Context

The biopharmaceutical industry, particularly the cell therapy field, is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property.

Comparison to Industry Standards

• The company faces competition from other biotechnology and pharmaceutical companies developing allogeneic CAR-NK or CAR-T cell therapies, including Adicet Bio, Allogene Therapeutics, Amgen, and others.
• The company's competitors also include companies developing targeted therapies, including small molecules or antibodies, for the same indications Artiva is targeting.
• The company's commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that Artiva may develop.

Corporate Governance

Legal Proceedings

• From time to time, the company may become involved in litigation or other legal proceedings.

Related Party Transactions

• The company has entered into several agreements with GC Cell and related entities concerning their NK cell therapy platform and manufacturing of their core products.
• In June 2024, the company entered into a services agreement (the Blackbird Services Agreement) with Blackbird Clinical, Inc. (Blackbird), an entity controlled by RA Capital Management, L.P.
• In November 2024, the company entered into a services agreement (the Carnot Services Agreement) with Carnot Pharma, LLC (Carnot), an entity controlled by RA Capital Management, L.P.

Stakeholder Impact

• The company's success depends on their ability to secure and maintain patent protection in the United States and other countries with respect to their current product candidates and any future product candidates they may develop.
• The company's success depends in large part on their ability to secure and maintain patent protection in the United States and other countries with respect to their current product candidates and any future product candidates they may develop.
• The company's success depends in large part on their ability to secure and maintain patent protection in the United States and other countries with respect to their current product candidates and any future product candidates they may develop.

Next Steps

• The company expects to report initial data on autoimmune indications from at least one of their Phase 1/1b trial or the basket IIT in the first half of 2025.

Key Dates

Keywords

AlloNK, NK cell therapy, autoimmune diseases, cancer, clinical trials, GC Cell, Affimed, B-NHL, SLE, LN